These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22486540)

  • 1. Imatinib mesylate-induced neutrophilic folliculitis in a teenager.
    García-Romero MT; Durán-McKinster C; de Ocariz MS; Carrasco-Daza D; Palacios-López C; Orozco-Covarrubias L; Ruiz-Maldonado R
    Int J Dermatol; 2012 Dec; 51(12):1529-30. PubMed ID: 22486540
    [No Abstract]   [Full Text] [Related]  

  • 2. Follicular mucinosis associated with imatinib (STI571).
    Yanagi T; Sawamura D; Shimizu H
    Br J Dermatol; 2004 Dec; 151(6):1276-8. PubMed ID: 15606531
    [No Abstract]   [Full Text] [Related]  

  • 3. Pseudoporphyria induced by imatinib mesylate.
    Pérez NO; Esturo SV; Viladomiu Edel A; Moreno AJ; Valls AT
    Int J Dermatol; 2014 Feb; 53(2):e143-4. PubMed ID: 23451912
    [No Abstract]   [Full Text] [Related]  

  • 4. Imatinib mesylate-induced pseudoporphyria in two children.
    Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
    Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
    Lau YM; Lam YK; Leung KH; Lin SY
    Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
    Machaczka M; Gossart M
    Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
    [No Abstract]   [Full Text] [Related]  

  • 7. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P; Das NK; Sil A; Chakrabarti P
    J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
    [No Abstract]   [Full Text] [Related]  

  • 8. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy.
    Dib EG; Ifthikharuddin JJ; Scott GA; Partilo SR
    Leuk Res; 2005 Feb; 29(2):233-4. PubMed ID: 15607374
    [No Abstract]   [Full Text] [Related]  

  • 9. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
    Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
    J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
    [No Abstract]   [Full Text] [Related]  

  • 10. Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.
    Mabed M; Elhefni AM; Damnhouri G
    Leuk Lymphoma; 2012 Nov; 53(11):2310-1. PubMed ID: 22462614
    [No Abstract]   [Full Text] [Related]  

  • 11. Imatinib-associated melanosis of the palate.
    Roeker LE; Wolanskyj AP
    Am J Hematol; 2014 May; 89(5):564. PubMed ID: 24030927
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib mesylate induced erythroderma.
    Sanghavi SA; Dongre AM; Khopkar US
    Indian J Dermatol Venereol Leprol; 2012; 78(3):408. PubMed ID: 22565463
    [No Abstract]   [Full Text] [Related]  

  • 13. Nonhematologic toxicity of imatinib mesylate in pediatric patients with chronic myelogenous leukemia: a predominance of musculoskeletal pain.
    Heym KM; Gressett Ussery SM; Trinkman H; Philpot LM
    J Pediatr Hematol Oncol; 2015 Mar; 37(2):e111-3. PubMed ID: 25374285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate induced skin hypopigmentation.
    Talwar V; Doval DC; Bhatia K
    J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypersensitivity pneumonitis related to imatinib mesylate.
    Bergeron A; Bergot E; Vilela G; Ades L; Devergie A; Espérou H; Socié G; Calvo F; Gluckman E; Ribaud P; Rousselot P; Tazi A
    J Clin Oncol; 2002 Oct; 20(20):4271-2. PubMed ID: 12377975
    [No Abstract]   [Full Text] [Related]  

  • 16. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
    Ramar K; Potti A; Mehdi SA
    J Clin Oncol; 2003 Jan; 21(1):172-3. PubMed ID: 12506189
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib mesylate-induced pseudoporphyria.
    Berghoff AT; English JC
    J Am Acad Dermatol; 2010 Jul; 63(1):e14-6. PubMed ID: 20542169
    [No Abstract]   [Full Text] [Related]  

  • 18. Skin fragility and blistering with imatinib mesylate.
    Verma SM; Murphy G
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):496-8. PubMed ID: 19925597
    [No Abstract]   [Full Text] [Related]  

  • 19. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.
    Rajda J; Phatak PD
    Am J Hematol; 2005 May; 79(1):80-1. PubMed ID: 15849772
    [No Abstract]   [Full Text] [Related]  

  • 20. [Adverse effects of imatinib mesylate].
    Isshiki I
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():404-7. PubMed ID: 17474438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.